SignatureFD
TRAX icon

SignatureFD’s First Tracks Biotherapeutics TRAX Stock Holding History

SignatureFD’s Portfolio TRAX Stock Details TRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.17K Buy
33
+26
+371% +$1.02K ﹤0.01% 3303
2026
Q2 		$141 Buy
+7
New +$131 ﹤0.01% 3434

Other funds holding TRAX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

SignatureFD's TRAX Position: Q3 2026 in Review

SignatureFD increased its First Tracks Biotherapeutics (TRAX) stake by 371% in Q3 2026, buying an estimated $1.02K and bringing the position to 33 shares worth $1.17K. The position accounts for ﹤0.01% of the portfolio, ranked #3303.

SignatureFD first reported a position in TRAX in Q2 2026 and has held it in 2 quarters since. 118 funds tracked by Wall St. Rank hold TRAX as of Q3 2026.

  • SignatureFD held 33 shares of First Tracks Biotherapeutics worth $1.17K as of Q3 2026.
  • SignatureFD bought 26 First Tracks Biotherapeutics shares in Q3 2026, an estimated $1.02K.
  • First Tracks Biotherapeutics made up ﹤0.01% of SignatureFD's portfolio in Q3 2026, its #3303 holding.
  • SignatureFD first reported a position in First Tracks Biotherapeutics in Q2 2026 and has held it in 2 quarters since.
  • 118 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q3 2026.

Based on SignatureFD's 13F filing for Q3 2026, filed 23 Oct 2026.